SCHEMBL615653

SCHEMBL615653

NC1CNC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6578879 0.95 CCR5 (0.43)
Bromide SCHEMBL28317628 0.95
Hydrochloric Acid SCHEMBL6578886 0.95
Hydrochloric Acid SCHEMBL10406911 0.95
Ammonia Solution, Strong SCHEMBL28159485 0.95
Hydrochloric Acid SCHEMBL28307145 0.91
Trimethylammonium SCHEMBL27899590 0.84
SCHEMBL20276680 0.79 CCR5 (0.32)
SCHEMBL3308474 0.79
SCHEMBL5381064 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 786 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166693-A1 METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 Design Therapeutics, Inc. 2024-05-23 US claimed
US-20240124491-A1 METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA Design Therapeutics, Inc. 2024-04-18 US claimed
CN-117751107-A Organic pyridine-pyrazole compounds and uses thereof 博善人工智能剑桥有限公司 2024-03-22 CN claimed
US-20240059698-A1 HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES ACCUTAR BIOTECHNOLOGY INC. (US) 2024-02-22 US claimed
WO-2024026056-A2 HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES ACCUTAR BIOTECHNOLOGY, INC. (US) 2024-02-01 WO claimed
CN-112204028-B tetrahydro-1H-pyrazino [2,1-a ] isoindoloquinoline compounds for use in the treatment of autoimmune diseases 豪夫迈·罗氏有限公司 2023-12-29 CN claimed
CN-117279636-A Methods and compounds for modulating myotonic muscular dystrophy type 1 设计治疗公司 2023-12-22 CN claimed
CN-111819176-B 4-azaindole compounds 百时美施贵宝公司 2023-12-15 CN claimed
CN-117241805-A Methods and compounds for treating friedel-crafts ataxia 设计治疗公司 2023-12-15 CN claimed
EP-4274583-A2 METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA Design Therapeutics, Inc. (US) 2023-11-15 EP claimed
US-20080275022-A1 Substituted Quinazolones as Anti-Cancer Agents ASTRAZENECA AB (SE) 2008-11-06 US claimed
WO-2008042639-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-04-10 WO claimed
CN-1956971-A Novel fused heterocycles and application thereof ASTRAZENECA AB (SE) 2007-05-02 CN claimed
EP-1761506-A1 SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS AstraZeneca AB (SE) 2007-03-14 EP claimed
WO-2005123696-A1 SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS ASTRAZENECA AB (SE) 2005-12-29 WO claimed
WO-2000063168-A1 SYNTHESIS OF AZETIDINE DERIVATIVES COELACANTH CHEMICAL CORPORATION (US) 2000-10-26 WO claimed
US-4943641-A 3-aminoazetidine, its salts, process for their preparation and intermediates of synthesis SANOFI (FR) 1990-07-24 US claimed
EP-0155870-B1 3-AMINOAZETIDINE, ITS SALTS, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES SANOFI (FR) 1989-04-26 EP claimed
US-4822895-A 3-aminoazetidine, its salts and intermediates of synthesis SOCIETE ANONYME - SANOFI (FR) 1989-04-18 US claimed
EP-0155870-A1 3-Aminoazetidine, its salts, process for their preparation and intermediates SANOFI (FR) 1985-09-25 EP claimed